Clinical Pipeline - B2 receptor antagonism | Pharvaris

Deucrictibant is the only oral bradykinin B2-receptor antagonist currently in clinical development, to our knowledge.

Pharvaris has a platform of novel, potent, and selective B2 receptor antagonist small molecules for the treatment of bradykinin-mediated diseases.

Molecule
Formulation
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Registration

deucrictibant
Immediate-Release Capsule
Extended-Release Tablet
HAE
On-Demand

HAE
Prophylaxis

PHAXXX
Undisclosed
Undisclosed

Treatment Strategy

During the shared decision process, people living with HAE and their treating physicians, may opt for treatment of attacks (on-demand treatment) or may prefer to prevent attacks (prophylactic treatment) based on clinical assessment and personal choice.

By bringing the promise of both these new treatment options to people living with HAE, Pharvaris aims to enable those with HAE to have fewer disruptions in their daily activities, resulting in an improved quality of life.

Product Summary

PHVS416 (deucrictibant immediate-release capsule)

  • Rapid exposure
  • Effective manifestation mitigation

Rapidly reaches therapeutic exposure within 30 minutes, making it optimally formulated for on-demand treatment of attacks. Its rapid* onset, one-dose symptom resolution, and oral delivery1 aims to fulfill an unmet need of people living with HAE.**

*Subjective
**Aspirational, to be confirmed with clinical data

*Footnotes

PHVS719 (deucrictibant extended-release tablet)

  • Sustained attack prevention

Maintains sustained therapeutic exposure for over 24 hours, allowing for once-daily administration to prevent HAE attacks. It is designed to significantly reduce HAE attack frequency.**

**Aspirational, to be confirmed with clinical data

Disease Focus

Deucrictibant

Deucrictibant is the only oral B2 receptor antagonist currently in clinical development. We aim to develop distinct, optimized formulations for both the on-demand treatment, through rapid onset of activity, and prophylactic treatment, through prolonged therapeutic activity, of HAE.

Explore our latest Publications, Posters and Presentations